Cargando…

Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy

BACKGROUND: The rate of radiation pneumonitis (RP) for patients receiving chemoradiotherapy has been various across studies. Whether it is related to different chemotherapy schedules used in combination with radiation therapy were evaluated in this study. New factors associated with RP were also inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dang, Jun, Li, Guang, Zang, Shuang, Zhang, Shuo, Yao, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120001/ https://www.ncbi.nlm.nih.gov/pubmed/25074618 http://dx.doi.org/10.1186/1748-717X-9-172

Ejemplares similares

Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer
por: Park, Young Hee, et al.
Publicado: (2013)

Cytokine Profiles of Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy with Regards to Radiation Pneumonitis Severity
por: Jeong, Bae Kwon, et al.
Publicado: (2021)

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
por: Tang, Shi, et al.
Publicado: (2023)

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition
por: Taugner, Julian, et al.
Publicado: (2021)

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study
por: Käsmann, Lukas, et al.
Publicado: (2023)

Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
por: Sakaguchi, Tadashi, et al.
Publicado: (2021)

Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients
por: Alharbi, Mohammed, et al.
Publicado: (2017)

Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022)

The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation
por: Ren, Chengbo, et al.
Publicado: (2018)

Clinical Outcomes in Stage III Non-small Cell Lung Cancer Patients Treated with Durvalumab After Sequential Or Concurrent Platinum-based Chemoradiotherapy – Single Institute Experience
por: Vrankar, Martina, et al.
Publicado: (2021)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non‐small cell lung cancer: Analysis of dose‐volume parameters
por: Katsui, Kuniaki, et al.
Publicado: (2020)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer
por: Park, Junhee, et al.
Publicado: (2018)

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Liver-directed Concurrent Chemoradiotherapy and Sequential Transarterial Radio-embolization
por: Noh, Minho, et al.
Publicado: (2021)

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
por: Doshita, Kosei, et al.
Publicado: (2022)

Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer
por: Saito, Satoshi, et al.
Publicado: (2020)

Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
por: Xu, Kunpeng, et al.
Publicado: (2021)

Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer
por: Abacioglu, Ufuk, et al.
Publicado: (2005)

The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy
por: Koo, Tae Ryool, et al.
Publicado: (2014)

Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Wei, Min, et al.
Publicado: (2018)

Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models
por: van Rossum, Peter S. N., et al.
Publicado: (2023)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer
por: Gupta, Arunima, et al.
Publicado: (2014)

Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey
por: Käsmann, Lukas, et al.
Publicado: (2020)

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)
por: Łazar-Poniatowska, Małgorzata, et al.
Publicado: (2021)

Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
por: Chang, Xiu-Jun, et al.
Publicado: (2016)

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy
por: Zhuang, Hongqing, et al.
Publicado: (2014)

Small Cell Carcinoma of the Larynx Treated by Concurrent Chemoradiotherapy: A Case Report
por: Nakahara, Susumu, et al.
Publicado: (2012)

Comparison of concurrent chemoradiotherapy versus sequential radiochemotherapy in patients with completely resected non-small cell lung cancer
por: Kim, Hwan-Ik, et al.
Publicado: (2016)

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
por: Guggenberger, J., et al.
Publicado: (2022)

Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
por: Yu, Xiaojuan, et al.
Publicado: (2015)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
por: Zhou, Qing, et al.
Publicado: (2020)

Pretreatment SUV(max) value to predict outcome in patients with stage III NSCLC receiving concurrent chemoradiotherapy
por: Yaprak, Gokhan, et al.
Publicado: (2019)

Lack of dose dependency for radiation pneumonitis after chemoradiotherapy with the use of tomotherapy for lung cancer
por: Masuoka, Yutaka, et al.
Publicado: (2022)

Prediction of Radiation Pneumonitis With Machine Learning in Stage III Lung Cancer: A Pilot Study
por: Yakar, Melek, et al.
Publicado: (2021)

Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up
por: Liu, Ming, et al.
Publicado: (2017)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kjub4h437m24t66c6r0lhuac69